Catalog Products » SARS-CoV-2 Spike protein (RBD, K417N, L452R, T478K, Avi & His Tag)-HRP

SARS-CoV-2 Spike protein (RBD, K417N, L452R, T478K, Avi & His Tag)-HRP

*This product has been discontinued!*
SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. The Delta Plus variant, also known as B.1.617.2.1 or AY.1, is considered a “subvariant” of the Delta version, which has a mutation (K417N) that allows the virus to better attack lung cells and potentially escape vaccines.
Z03690
Ask us a question
Product Introduction
Species SARS-CoV-2
Protein Construction

Expressed with the mutations of K417N, L452R, T478K.

Spike RBD (Arg319-Ser591)
Accession # P0DTC2
Avi Poly-His
N-term C-term
Conjugate HRP
Biological Activity This protein is validated to bind with human ACE2 (Cat. No. Z03516) in functional ELISA assay.
Expression System CHO
Application The optimal dilution ratio should be determined by the end user for specific applications.
ELISA 1:1000
Formulation Supplied as a solution in PBS, pH 7.4, 0.1% ProClin 300.
Storage & Stability Upon receiving, this product remains stable for up to 3 months at 2-8°C. Protect from light.

Background
Target Background SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2) also known as 2019-nCoV (2019 Novel Coronavirus) is a virus that causes illnesses ranging from the common cold to severe diseases. As of May 2021, three sublineages have been found. Despite its name, B.1.617.3 was the first sublineage of this variant to be detected, in October 2020 in India. This sublineage has remained relatively uncommon compared to the two other sublineages, B.1.617.1 (also known as variant Kappa) and B.1.617.2 (also known as variant Delta), both of which were first detected in December 2020. This variant has the double mutations E484Q and L452R in the spike proteins. Emerging research suggests the variant may be more transmissible than previously evolved ones. The Delta Plus variant, also known as B.1.617.2.1 or AY.1, is considered a “subvariant” of the Delta version, which has a mutation (K417N) that allows the virus to better attack lung cells and potentially escape vaccines.
Synonyms B.1.617.2.1; Delta Plus variant; AY.1
References 1. Emergence of a novel SARS-CoV-2 strain in Southern California, USA.
2. New California Variant May Be Driving Virus Surge There, Study Suggests.
3. Tracking SARS-CoV-2 variants.
4. What You Need to Know About the Delta Variant.

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.


feedback

Do you like the current new website?

Hate

Dislike

Neutral

Like

Love

*